On February 12, 2025, the Centers for Medicare & Medicaid Services (CMS) announced a landmark initiative: the MAHA ELEVATE program, allocating $100 million through the Center for Medicare and Medicaid Innovation (CMMI) to support functional medicine and lifestyle intervention models.
This is not incremental policy adjustment. It's the first time the federal government has formally recognized and funded root-cause, lifestyle-based medicine at scale. For patients exploring peptide therapy and practitioners integrating it into care models, the implications are profound.
MAHA ELEVATE signals a tectonic shift in how American healthcare approaches chronic disease,away from symptom management and toward metabolic restoration, mitochondrial health, and preventative intervention. Peptide therapy, long relegated to the edges of mainstream medicine, now sits squarely within this framework.
Here's what the program means, what interventions qualify, how it shifts the practitioner field, and how intelligence systems like Gabriel are helping practitioners handle this new terrain.
What Is MAHA ELEVATE?
MAHA stands for "Make America Healthy Again",a policy initiative championed by Robert F. Kennedy Jr. during his independent presidential campaign and subsequently integrated into federal health policy after his endorsement of President Trump.
The core premise: chronic disease in America is a metabolic and lifestyle crisis, not a genetic inevitability. Conditions like type 2 diabetes, obesity, cardiovascular disease, and autoimmune disorders are driven by environmental factors,diet, toxins, stress, sleep, movement,and are thus potentially reversible through root-cause interventions.
The ELEVATE Framework
ELEVATE stands for:
- Evidence-based functional medicine
- Lifestyle interventions
- Environmental toxin reduction
- Value-based outcomes
- Access to alternative therapies
- Technology-enabled care
- Empowerment of patient agency
- Creating reimbursement pathways for functional medicine services
- Funding practitioner training in lifestyle intervention protocols
- Establishing data collection infrastructure to demonstrate outcomes
- Signaling to private insurers that functional medicine is a priority
- Insulin sensitivity optimization (dietary, exercise, pharmacologic)
- Mitochondrial support therapies (NAD+ precursors, CoQ10, peptides like MOTS-C)
- Continuous glucose monitoring (CGM) for metabolic feedback
- Time-restricted eating and metabolic flexibility training
- Medical nutrition therapy (MNT) for chronic disease
- Elimination diets and food sensitivity testing
- Micronutrient optimization (testing and repletion)
- Gut microbiome analysis and support (probiotics, prebiotics, targeted protocols)
- Metabolic optimization: Semaglutide, tesamorelin, CJC-1295/ipamorelin
- Tissue repair and recovery: BPC-157, TB-500, GHK-Cu
- Mitochondrial function: MOTS-C, Humanin, other mitochondrial-derived peptides
- Immune modulation: Thymosin alpha-1, LL-37
- Cognitive and neuroprotection: Semax, Selank, cerebrolysin
- Bioidentical hormone replacement therapy (BHRT)
- Thyroid optimization beyond TSH suppression
- Testosterone replacement therapy (when clinically indicated)
- Estrogen/progesterone balancing for metabolic and cognitive health
- Heavy metal testing and chelation (when indicated)
- Mold exposure assessment and remediation support
- Endocrine disruptor reduction counseling
- Toxin binder protocols (activated charcoal, zeolite, etc.)
- Meditation and mindfulness-based stress reduction (MBSR)
- Heart rate variability (HRV) training
- Breathwork protocols (Wim Hof, Box Breathing, etc.)
- Neurofeedback and biofeedback
- Personalized exercise prescription
- Resistance training for metabolic health
- Zone 2 cardio for mitochondrial capacity
- High-intensity interval training (HIIT) protocols
- Sleep studies and disorder treatment
- Circadian rhythm restoration (light therapy, meal timing)
- Pharmacologic sleep support (melatonin, peptides like DSIP)
- Per-patient-per-month (PPPM) payments for coordinated functional medicine care
- Outcome-based bonuses for achieving metabolic reversal targets (e.g., diabetes remission, BMI reduction, medication deprescribing)
- Training grants for practitioners to gain functional medicine certification
- The Institute for Functional Medicine (IFM)
- American Academy of Anti-Aging Medicine (A4M)
- American College of Lifestyle Medicine (ACLM)
- Certification programs in functional medicine
- Peptide therapy training modules
- Metabolic optimization protocols
- Continuous education on emerging therapies
- Patient demographics and baseline health status
- Interventions administered (peptides, nutrition, lifestyle, etc.)
- Outcomes (metabolic markers, symptoms, quality of life, medication changes)
- Adverse events
- Legitimizing peptide therapy as a recognized intervention within federally funded programs
- Creating reimbursement pathways for peptide administration and monitoring
- Requiring quality standards (sourcing from licensed pharmacies, CoA verification, outcomes tracking)
- Peptide therapy was almost entirely out-of-pocket
- Finding knowledgeable practitioners was challenging
- Insurance didn't cover consults, testing, or peptides themselves
- Limited accountability or outcomes tracking
- Medicare/Medicaid patients in participating practices can access peptide therapy with reimbursement
- Practitioner training programs are creating a larger, more skilled workforce
- Quality standards are becoming enforceable (pharmacies must be licensed, peptides must be documented)
- Outcomes are tracked systematically
- Source peptides from state-licensed compounding pharmacies (503A or 503B)
- Document Certificates of Analysis (CoA) for every batch
- Report peptide brands and lot numbers to the FMOR database
- Track adverse events and report to CMS
- Synthesizes latest research on peptides, metabolic interventions, biomarkers
- Recommends evidence-based protocols based on patient context
- Flags drug interactions, contraindications, and safety signals
- Automates data entry for the Functional Medicine Outcomes Registry
- Tracks patient progress on metabolic markers, symptoms, quality of life
- Generates reports demonstrating value for reimbursement justification
- Monitors new studies, case reports, clinical signals on peptide therapies
- Curates actionable insights from the broader functional medicine literature
- Alerts practitioners to emerging therapies or regulatory changes
- Generates personalized educational content for patients on peptides, protocols, lifestyle interventions
- Supports adherence through automated check-ins and progress tracking
- Empowers patients with data and understanding
- Tracks peptide sourcing, lot numbers, CoAs
- Flags quality concerns with specific compounding pharmacies
- Maintains a verified supplier database aligned with MAHA quality standards
- Economic: Reversing chronic disease reduces long-term medical costs
- Social: Healthier populations are more productive, resilient, engaged
- Political: MAHA ELEVATE represents a bipartisan recognition that the current system isn't working
- Diabetes remission rates
- Medication deprescribing (especially for chronic conditions)
- Quality of life improvements
- Healthcare cost reduction (fewer ER visits, hospitalizations, procedures)
The $100M funding is designed to support pilot programs, practitioner training, patient access initiatives, and data infrastructure to track outcomes from functional medicine approaches.
Why This Matters
Medicare and Medicaid are the largest payers in the U.S. healthcare system, covering over 140 million Americans. When CMS funds something, it doesn't just subsidize care,it legitimizes it.
For decades, functional medicine practitioners have operated largely outside insurance reimbursement systems, forcing patients to pay out-of-pocket. MAHA ELEVATE changes this dynamic by:
The downstream effect: peptide therapy, once considered "alternative" or "experimental," is increasingly positioned as part of a federally recognized approach to chronic disease reversal.
What Interventions Qualify?
The MAHA ELEVATE program is intentionally broad, encompassing a range of functional medicine and lifestyle interventions. Based on the CMS guidance documents released in March 2025, qualifying interventions include:
1. Metabolic Restoration Protocols
2. Nutritional Interventions
3. Peptide Therapy
This is the category most directly relevant to Matter's community. CMS explicitly lists peptide therapy as a qualifying intervention under MAHA ELEVATE, provided it is administered under practitioner supervision with documented rationale and outcomes tracking.
Qualifying peptide applications include:
Critical requirement: Peptides must be sourced from licensed compounding pharmacies (503A or 503B) or used in approved research contexts. Grey market or unverified sources are explicitly excluded from reimbursement eligibility.
4. Hormone Optimization
5. Detoxification and Environmental Medicine
6. Mind-Body and Stress Reduction
7. Exercise as Medicine
8. Sleep Optimization
How the Practitioner field Is Shifting
MAHA ELEVATE creates new incentives and infrastructure for practitioners to adopt functional medicine models.
Reimbursement Pathways
Under the CMMI Innovation Center framework, practices participating in MAHA ELEVATE pilots can receive:
This shifts the economic model. Previously, functional medicine was cash-pay, limiting access to affluent patients. Now, Medicare and Medicaid patients can access these services, and practitioners can be reimbursed.
Practitioner Training and Certification
CMS has partnered with functional medicine organizations including:
Funding is available for:
The goal is to create a credentialed workforce capable of delivering evidence-based functional medicine at scale.
Data Infrastructure and Outcomes Tracking
A key component of MAHA ELEVATE is the Functional Medicine Outcomes Registry (FMOR), a CMS-funded database tracking:
This registry serves two purposes:
1. Evidence generation: Building a real-world evidence base for functional medicine interventions
2. Reimbursement justification: Demonstrating value to justify continued funding and expansion
Practitioners participating in MAHA ELEVATE are required to report data to FMOR, creating a feedback loop between clinical practice and policy.
Peptide Therapy in the MAHA Framework
Peptide therapy has long existed in a regulatory grey zone,legal when compounded under state pharmacy law, but outside mainstream medicine and insurance coverage.
MAHA ELEVATE changes this by:
What This Means for Patients
Before MAHA ELEVATE:
After MAHA ELEVATE:
This doesn't make peptides a covered Medicare benefit overnight, but it creates the infrastructure for that to happen as evidence accumulates.
Quality Control Becomes Mandatory
One unintended but critical benefit of MAHA ELEVATE: quality control is no longer optional.
To participate in the program and receive reimbursement, practitioners must:
This creates accountability. Grey market peptides, unverified suppliers, and substandard compounding are incompatible with program participation.
For companies like Matter, which have built their model on pharmaceutical-grade quality and CoA verification, MAHA ELEVATE is validation. The federal government is essentially mandating the quality standard Matter has always maintained.
How Gabriel Fits Into the MAHA field
Gabriel is a health intelligence platform designed to help practitioners handle the complexity of functional medicine, peptide therapy, and personalized care at scale.
MAHA ELEVATE creates a new challenge for practitioners: they need to deliver individualized, evidence-based care while managing data reporting requirements, staying current on emerging research, and optimizing patient outcomes.
Gabriel is being built to solve this.
What Gabriel Does for Practitioners
1. Clinical Decision Support
2. Outcomes Tracking and FMOR Integration
3. Research Intelligence
4. Patient Education and Engagement
5. Quality Verification
Why This Matters Now
MAHA ELEVATE is creating a functional medicine boom. Thousands of practitioners are entering the space, many without deep expertise in peptides or metabolic optimization.
Gabriel acts as a force multiplier,allowing practitioners to deliver high-quality, evidence-based care even if they're early in their functional medicine journey. It's the infrastructure layer that makes MAHA ELEVATE scalable.
The Bigger Picture: Functional Medicine Goes Mainstream
MAHA ELEVATE is not just about peptides. It's about a paradigm shift in American medicine,from disease management to health optimization, from symptom suppression to root-cause resolution.
Peptide therapy is part of this shift because peptides are signaling molecules. They don't mask symptoms; they modulate biological processes. They fit the functional medicine ethos: work with the body's own systems, optimize physiology, restore function.
The implications extend beyond healthcare:
For patients, this means access. Functional medicine is no longer just for people who can afford cash-pay concierge care. It's becoming available to Medicare and Medicaid populations,the people who need it most.
For practitioners, this means opportunity. The market for functional medicine is expanding rapidly, and reimbursement pathways are opening.
For companies like Matter, this means validation. The quality standards, transparency, and research-first approach that Matter has built from day one are now being mandated at the federal level.
What Comes Next
MAHA ELEVATE is a pilot program, not a permanent policy shift. Success depends on demonstrating outcomes.
Key metrics CMS will track:
If the data shows functional medicine works,and early signals are promising,MAHA ELEVATE will expand. More funding, broader coverage, deeper integration into standard care.
If the data is weak, the program will sunset.
This is why outcomes tracking matters. Every practitioner participating in MAHA ELEVATE is contributing to an evidence base that will determine the future of functional medicine in the U.S.
Peptide therapy, specifically, needs rigorous real-world data. Anecdotal reports are compelling, but systematic outcomes collection is what convinces policymakers and payers.
Gabriel is being designed to facilitate this,making it easy for practitioners to contribute high-quality data while delivering excellent patient care.
The Bottom Line
The CMS MAHA ELEVATE program represents a historic moment: the federal government is funding root-cause, lifestyle-based medicine at scale and explicitly including peptide therapy as a qualifying intervention.
For patients, this means access to therapies that were previously out of reach financially. For practitioners, this means reimbursement for delivering the kind of care they've long wanted to provide. For the functional medicine field, this means legitimacy and growth.
Peptide therapy fits squarely within the MAHA framework. Peptides are not symptom suppressors,they are biological signaling molecules that restore function, optimize metabolism, and support the body's own healing mechanisms.
The requirement for pharmaceutical-grade sourcing, CoA verification, and outcomes tracking aligns perfectly with Matter's foundational principles. Quality has always been non-negotiable for research applications. Now, it's becoming non-negotiable for clinical practice too.
Gabriel, as a health intelligence platform, is positioned to help practitioners handle this new field,synthesizing research, tracking outcomes, ensuring quality, and scaling evidence-based care.
MAHA ELEVATE is not the end of the journey. It's the beginning. The next decade will determine whether functional medicine becomes the standard of care or remains a niche alternative. The data collected now will make that decision.
For those working at the intersection of peptide therapy, functional medicine, and patient care, the opportunity,and the responsibility,has never been greater.